bioAffinity Technologies Awarded Membership in Early Detection Research Network
FEBRUARY 28, 2018
(SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer
diagnostics company, today announced it had been approved for membership in the Early
Detection Research Network (EDRN), an initiative of the National Cancer Institute (NCI). EDRN
brings together dozens of institutions to help accelerate the translation of biomarker
information into clinical applications and to evaluate new ways of testing cancer in its earliest
stages and for cancer risk.
“Collaboration with National Cancer Institute’s Early Detection Research Network is an
important step in the development of CyPath © Lung, our non-invasive, early lung cancer test.
EDRN also offers valuable resources to advance our promising oncological diagnostics for
prostate and bladder cancers,” said Maria Zannes, President and Chief Executive Officer of
bioAffinity Technologies. “EDRN and its members share many of our objectives including
acceleration for testing of promising technologies for early detection of cancer and promoting
collaboration among academic and industrial leaders to advance the clinical application of tests
such as CyPath © Lung for early cancer detection.”
bioAffinity Technologies’ Executive Vice President Vivienne Rebel, PhD, MD, and Director of
Operations Xavier Reveles, MS GC(ASCP) cm will attend next week’s 10th EDRN Scientific
Workshop from March 6-8, 2018 in Bethesda, MD that focuses on standards and regulatory
science, novel technologies for precision detection, imaging, clinical and validation science,
alliances and consortia on biomarkers, and non-profit foundations support for biomarkers.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage
company that develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics
using breakthrough technology that preferentially targets cancer cells. Research and
optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories
and at the University of Texas San Antonio. The Company’s initial product is CyPath® Lung, a
diagnostic assay for the detection of early-stage lung cancer.